13F Data
13F filer · CIK 2081668

Royalty Pharma Sub-Manager, LLC

New York, NY · filing since Q4 2025 · last filing Aug 21, 2026
Reported value
$241.9M
+$69.2M vs prior
Positions
4
New / sold out
1 / 1
Added / reduced
0 / 0
Turnover
17.7%
buys $54.1M · sells $36.6M
Top-10 weight
100.0%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
NewKAILERA THERAPEUTICS+2,455,357–+$54.1M

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
Sold outBIOCRYST PHARMACEUTICALS INC-3,846,154-100.0%$-36.6M

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2025: $171.3MQ1 2026: $172.8MQ2 2026: $241.9M
Q4 2025Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1CYTOKINETICS, INCCOM980,392$83.5M34.52%
2ZENAS BIOPHARMA, INC.COM2,388,150$60.6M25.05%
3KAILERA THERAPEUTICSCOM2,455,357$54.1M22.36%
4BIOHAVEN LTDCOM2,936,507$43.7M18.06%